Meristem Family Wealth’s Moderna MRNA Stock Holding History

Meristem Family Wealth’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,662	Closed	-$640K	–	418
2021 Q3	$640K	Buy	+1,662	New	+$613K	0.06%	188

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Meristem Family Wealth's MRNA Position: Q4 2021 in Review

Meristem Family Wealth sold out of Moderna (MRNA) in Q4 2021, closing a stake of 1,662 shares — an estimated $640K sold.

Meristem Family Wealth first reported a position in MRNA in Q3 2021 and held it in 1 quarter. The position peaked at $640K in Q3 2021. 1,110 funds tracked by Wall St. Rank hold MRNA as of Q4 2021.

Meristem Family Wealth reported no remaining Moderna position as of Q4 2021 after selling out during the quarter.
Meristem Family Wealth sold 1,662 Moderna shares in Q4 2021, an estimated $640K.
Meristem Family Wealth first reported a position in Moderna in Q3 2021 and held it in 1 quarter.
Meristem Family Wealth's Moderna position peaked at $640K in Q3 2021.
1,110 funds tracked by Wall St. Rank held Moderna as of Q4 2021.

Based on Meristem Family Wealth's 13F filing for Q4 2021, filed 10 Feb 2022.